Veterinary Vaccine Adjuvants Market Set to Surge Past US$ 703 Million by 2031 – Growth Plus Reports

Newark, New Castle, USA, April 18, 2023 (GLOBE NEWSWIRE) -- According to a new analysis by Growth Plus Reports, the global Veterinary Vaccine Adjuvants Market is estimated to be worth US$ 703 million by 2031, with a revenue CAGR of 5.90%. The study examines the key strategies, factors and prospects, competitive landscape, evolving industry patterns, market size, financial information and forecasts, and potential business opportunities.

Key Takeaways:

• The increasing prevalence of several diseases in animals will drive market growth.

• Increasing awareness of animal health will support market revenue growth.

• North America will dominate the global market with the largest revenue share.

Request a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/veterinary-vaccine-adjuvants-market/8636

                       Veterinary Vaccine Adjuvants Market Scope

Market Drivers
The increasing use of adjuvants in vaccinations, the growing quantity of animals and diseases associated with them, and the high frequency of a variety of disorders are the primary factors driving the revenue growth of the veterinary vaccine adjuvants market. Furthermore, increased government support and enhanced veterinary healthcare infrastructure are expected to contribute to market revenue growth.

Market Segmentation
Growth Plus Reports has analyzed the global veterinary vaccine adjuvants market from four perspectives: Type, Route of Administration, and Region.

Type Segmentation: Based on the material, the veterinary vaccine adjuvants market is segmented into oil emulsion adjuvants, alum and calcium salts, nanoparticles and microparticles, liposomes and archaeosomes, and others. The alum and calcium salts segment dominates the market with the largest revenue share because these adjuvants are relatively safe and have minimal side effects.

Route of Administration Segmentation: Based on the route of administration, the veterinary vaccine adjuvants market is segmented into subcutaneous, intramuscular, oral, and others. The intramuscular segment dominates the market with the largest revenue share because this method of administration improves the efficacy of a vaccination.

Regional Growth Dynamics
Based on the region, the global veterinary vaccine adjuvants market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America dominates the global veterinary vaccine adjuvants market with the largest revenue share. The growing pet adoption, rising pet health insurance, improved veterinary healthcare infrastructure, rising disease prevalence in animals, greater animal health awareness, and increased government assistance are the major factors responsible for North America's significant revenue share in the global market. 

Request for Customization – https://www.growthplusreports.com/inquiry/customization/veterinary-vaccine-adjuvants-market/8636

Competitive Landscape
The following companies are important players in the global veterinary vaccine adjuvants market:

• Bioveta AS
• Merck & Co. Inc.
• Phibro Animal Health Corporation
• SEPPIC
• SPI Pharma
• MVP Laboratories
• Croda International Plc
• Zoetis
• SDA Bio

There is moderate competition in the veterinary vaccine adjuvants market. To introduce novel drugs and products, the major players in the market emphasize research and development. Major companies often engage in mergers and acquisitions to enhance their market share.

Recent developments:

• Evonik Industries AG introduced squalene in December 2022, which is not derived from animals but is useful in vaccinations and other medicinal applications. PhytoSquene, the first commercially available squalene derived from amaranth oil, is used as an adjuvant in parenteral dosage forms. It meets the demand for a consistent commercial supply of squalene that is not sourced from animals.
• Two genotypes of the porcine circovirus type 2 (PCV2 genotypes A and B) were included in the CircoMAX vaccine, which Zoetis launched in Europe in May 2021, to provide protection against PCV2 and Mycoplasma hyopneumoniae.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem
   2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources
   4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2022)
   3. Regulatory Landscape
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL VETERINARY VACCINE ADJUVANTS MARKET - ANALYSIS & FORECAST, BY TYPE
   1. Oil Emulsion Adjuvants
   2. Alum and Calcium Salts
   3. Nanoparticles and Microparticles
   4. Liposomes and Archaeosomes
   5. Others
6. GLOBAL VETERINARY VACCINE ADJUVANTS MARKET - ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
   1. Subcutaneous
   2. Intramuscular
   3. Oral
   4. Others

VETERINARY VACCINE ADJUVANTS MARKET TOC

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8636

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• 'Business Profile' of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at - https://www.growthplusreports.com/report-store

Browse Latest Healthcare Related Reports:

Pneumonia Testing Market by Type (Bacterial, Viral), Test Type (Blood Test, Sputum Test), Method (Immunodiagnostic, Molecular Diagnostics), Technology (Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence), End User (Hospitals, Diagnostic Centers) - Global Outlook and Forecast 2023-2031

Positive Expiratory Pressure Devices Market by Product Type (Face Mask PEP Devices, Mouthpiece PEP Devices), Application (Atelectasis, Bronchiectasis), End User (Hospitals & Clinics, Ambulatory Surgical Centers) – Global Outlook & Forecast 2023-2031

Aortic Valve Replacement Devices Market by Surgery (Open Surgery, Minimally Invasive Surgery), Product (Transcatheter Aortic Valve, Suture-less Valve), End User (Hospitals, Ambulatory Surgery Centers) - Global Outlook and Forecast 2023-2031

Antiplatelet Drugs Market by Drug Class (Irreversible Cyclooxygenase Inhibitors, Thromboxane inhibitors), Route of Administration (Oral, Parenteral), Indications (Acute Coronary Syndrome, Acute Ischemic Stroke) - Global Outlook and Forecast 2023-2031

Pharmaceutical Quality Management Systems Market by Deployment (On-cloud, On-premises), Solution Type (Audit Management, Document Management), End User (Pharmaceutical Companies, Contract Research Organizations) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020".